Biontech and Pfizer start a study on the efficacy and safety of a new anti-Corona vaccine
The German company Biontech for Pharmaceutical Industries and its American partner, Pfizer, have started a new study on the effectiveness and safety of a new potential vaccine against Corona.
The two companies indicated today, Wednesday, that the potential vaccine is based on the same RNA technology as the current vaccine and will be examined in the second clinical phase of the study on about 200 participants in the United States.
The two companies added that the spinal protein of this "potential next-generation vaccine" will be modified with the aim of increasing the amount of immune response and thus increasing protection against infection with Covid-19.
The two companies said that this vaccine will be "the first of a series of candidate vaccines with a modified design", and the two companies continued that they are pursuing a long-term vaccine strategy based on science in order to produce "wider, longer-lasting and more robust immune responses" in the face of Corona infection.
Follow our latest local and sports news and the latest political and economic developments via Google news